Raggi, Daniele

Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study

Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology

Bladder and Urothelial Cancer TreatmentsCancer Immunotherapy and Biomarkers

Cited by 741

An Open-Label Randomized Phase 2 Study of Durvalumab Alone or in Combination with Tremelimumab in Patients with Advanced Germ Cell Tumors (APACHE): Results from the First Planned Interim Analysis

Necchi, A., Giannatempo, P., Raggi, D., Mariani, L., Colecchia, M., Farè, E., Monopoli, F., Calareso, G., Ali, S. M., Ross, J. S., et al. (2019) · European Urology

Testicular diseases and treatmentsCancer Immunotherapy and Biomarkers

Cited by 78

Stool Microbiome Signature Associated with Response to Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Cancer

Pederzoli, F., Riba, M., Venegoni, C., Marandino, L., Bandini, M., Alchera, E., Locatelli, I., Raggi, D., Giannatempo, P., Provero, P., et al. (2024) · European Urology

Cancer Immunotherapy and BiomarkersGut microbiota and health

Cited by 33

An open-label, single-group, phase 2 study of brentuximab vedotin as salvage therapy for males with relapsed germ-cell tumors (GCT): Results at the end of first stage (FM12GCT01).

Necchi, A., Magazzu, D., Anichini, A., Raggi, D., Giannatempo, P., Nicolai, N., Colecchia, M., Paolini, B., Coradeschi, E., Tassi, E., et al. (2016) · Journal of Clinical Oncology

Testicular diseases and treatmentsLymphoma Diagnosis and Treatment

Cited by 17